Systemic Involvement in Immunoglobulin G4-Related Ophthalmic Disease

References

• Stone JH, Zen Y, and Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539–551. doi:10.1056/NEJMra1104650.
   PubMed Web of Science ®Google Scholar
• Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–1192. doi:10.1038/modpathol.2012.72.
   PubMed Web of Science ®Google Scholar
• Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–738. doi:10.1056/NEJM200103083441005.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European league against rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77–87. doi:10.1136/annrheumdis-2019-216561.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Terao C. Genetic analysis of IgG4-related disease. Mod Rheumatol. 2020;30(1):17–23. doi:10.1080/14397595.2019.1621000.
   PubMed Web of Science ®Google Scholar
• Kobak S. May IgG4-related disease be reactivated by SARS-CoV-2 infection? Reumatologia. 2022;60(2):161–162. doi:10.5114/reum.2022.115985.
   PubMed Web of Science ®Google Scholar
• Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. Dec, 2020;16(12):702–714. doi:10.1038/s41584-020-0500-7.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Ohara M, Suzuki C, et al. Elevated IgG4 concentrations in serum of patients with Mikulicz’s disease. Scand J Rheumatol. 2004;33(6):432–433. doi:10.1080/03009740410006439.
   PubMed Web of Science ®Google Scholar
• Lai KKH, Chan RYC, Chin JKY, et al. Upper cranial nerve involvement and immunoglobulin G4-related optic neuropathy. Ophthalmology. 2020;127(5):699–703. doi:10.1016/j.ophtha.2019.11.015.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Deshpande V, Stone JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum. Jun, 2014;43(6):806–817. doi:10.1016/j.semarthrit.2013.11.008.
   PubMed Web of Science ®Google Scholar
• Wu A, Andrew NH, McNab AA, Selva D. Bilateral IgG4-related ophthalmic disease: a strong indication for systemic imaging. Br J Ophthalmol. Oct, 2016;100(10):1409–1411. doi:10.1136/bjophthalmol-2015-307437.
   PubMed Web of Science ®Google Scholar
• Park J, Lee MJ, Kim N, Kim JE, Park SW, Choung HK, Khwarg SI. Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2018;102(6):736–741. doi:10.1136/bjophthalmol-2017-310584.
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH. The clinical spectrum of IgG4-related disease. Autoimmun Rev. 2014;13(12):1203–1210. doi:10.1016/j.autrev.2014.08.013.
   PubMed Web of Science ®Google Scholar
• Abraham M, Khosroshahi A. Diagnostic and treatment workup for IgG4-related disease. Expert Rev Clin Immunol. 2017;13(9):867–875. doi:10.1080/1744666X.2017.1354698.
   PubMed Web of Science ®Google Scholar
• Lai KKH, Chu WCW, Li EYM, et al. Radiological determinants of complicated immunoglobulin G4-related ophthalmic disease: a territory-wide cohort study. Asia Pac J Ophthalmol (Phila). 2022;11(5):417–424. doi:10.1097/APO.0000000000000552.
   PubMed Web of Science ®Google Scholar
• Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30. doi:10.3109/s10165-011-0571-z.
   PubMed Web of Science ®Google Scholar
• Goto H, Takahira M, Azumi A, Japanese Study Group for IgG4-Related Ophthalmic Disease. Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol. 2015;59(1):1–7. doi:10.1007/s10384-014-0352-2.
   PubMed Web of Science ®Google Scholar
• Koizumi S, Kamisawa T, Kuruma S, et al. Clinical features of IgG4-related dacryoadenitis. Graefes Arch Clin Exp Ophthalmol. 2014;252(3):491–497. doi:10.1007/s00417-013-2541-y.
   PubMed Web of Science ®Google Scholar
• Hagiya C, Tsuboi H, Yokosawa M, et al. Clinicopathological features of IgG4-related disease complicated with orbital involvement. Mod Rheumatol. 2014;24(3):471–476. doi:10.3109/14397595.2013.844307.
   PubMed Web of Science ®Google Scholar
• Ebbo M, Patient M, Grados A, et al. Ophthalmic manifestations in IgG4-related disease: clinical presentation and response to treatment in a French case-series. Medicine. 2017;96(10):e6205. doi:10.1097/MD.0000000000006205.
   PubMed Web of Science ®Google Scholar
• Yu WK, Kao SC, Yang CF, Lee FL, Tsai CC. Ocular adnexal IgG4-related disease: clinical features, outcome, and factors associated with response to systemic steroids. Jpn J Ophthalmol. 2015;59(1):8–13. doi:10.1007/s10384-014-0353-1.
   PubMed Web of Science ®Google Scholar
• Sato Y, Ohshima K, Ichimura K, et al. Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int. 2008;58(8):465–470. doi:10.1111/j.1440-1827.2008.02257.x.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang P, Li J, et al. Different clinical patterns of IgG4-RD patients with and without eosinophilia. Sci Rep. 2019;9(1):16483. doi:10.1038/s41598-019-52847-6.
   PubMedGoogle Scholar
• Kubota T, Katayama M, Moritani S, Yoshino T. Serologic factors in early relapse of IgG4-related orbital inflammation after steroid treatment. Am J Ophthalmol. 2013;155(2):373–379.e1. doi:10.1016/j.ajo.2012.07.024.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang P, Lin W, et al. Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy. Arthritis Res Ther. 2019;21(1):44. doi:10.1186/s13075-019-1828-8.
   PubMedGoogle Scholar
• Lai KKH, Li EYM, Chan RYC, et al. Treatment outcomes and their determinants of IgG4-related ophthalmic disease: a territory-wide cohort study. Br J Ophthalmol. 2022:bjophthalmol-2021–320936. doi:10.1136/bjo-2021-320936.
   Web of Science ®Google Scholar
• Wang L, Zhang P, Wang M, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther. 2018;20(1):65. doi:10.1186/s13075-018-1567-2.
   PubMedGoogle Scholar
• Mizushima I, Tsuge S, Fujisawa Y, et al. Different factors underlie recurrent and de novo organ involvement in immunoglobulin G4-related disease. Rheumatology (Oxford). 2020;59(3):513–518. doi:10.1093/rheumatology/kez321.
   PubMed Web of Science ®Google Scholar
• Koizumi S, Kamisawa T, Kuruma S, et al. Organ correlation in IgG4-related diseases. J Korean Med Sci. 2015;30(6):743–748. doi:10.3346/jkms.2015.30.6.743.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH, ACR/EULAR IgG4-RDClassificationCriteriaCommittee. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78(3):406–412. doi:10.1136/annrheumdis-2018-214603.
   PubMed Web of Science ®Google Scholar
• Evans RDR, Cargill T, Goodchild G, et al. Clinical manifestations and long-term outcomes of IgG4-related kidney and retroperitoneal involvement in a United Kingdom IgG4-related disease cohort. Kidney Int Rep. 2018;4(1):48–58. doi:10.1016/j.ekir.2018.08.011.
   PubMed Web of Science ®Google Scholar
• Ikeura T, Miyoshi H, Shimatani M, Uchida K, Takaoka M, Okazaki K. Long-term outcomes of autoimmune pancreatitis. World J Gastroenterol. 2016;22(34):7760–7766. doi:10.3748/wjg.v22.i34.7760.
   PubMed Web of Science ®Google Scholar
• Fujimori N, Ito T, Igarashi H, et al. Retroperitoneal fibrosis associated with immunoglobulin G4-related disease. World J Gastroenterol. 2013;19(1):35–41. doi:10.3748/wjg.v19.i1.35.
   PubMed Web of Science ®Google Scholar
• Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: what a hematologist needs to know. Haematologica. 2019;104(3):444–455. doi:10.3324/haematol.2018.205526.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Okamura K, Kise Y, et al. Effectiveness of imaging modalities for screening IgG4-related dacryoadenitis and sialadenitis (Mikulicz’s disease) and for differentiating it from Sjögren’s syndrome (SS), with an emphasis on sonography. Arthritis Res Ther. 2015;17(1):223. doi:10.1186/s13075-015-0751-x.
   PubMed Web of Science ®Google Scholar
• Behzadi F, Suh CH, Jo VY, Shanmugam V, Morgan EA, Guenette JP. Imaging of IgG4-related disease in the head and neck: a systematic review case series, and pathophysiology update. J Neuroradiol. 2021;48(5):369–378. doi:10.1016/j.neurad.2021.01.006.
   PubMed Web of Science ®Google Scholar
• Mota MMDS, Bezerra ROF, Garcia MRT. Practical approach to primary retroperitoneal masses in adults. Radiol Bras. 2018;51(6):391–400. doi:10.1590/0100-3984.2017.0179.
   PubMedGoogle Scholar
• Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-activated protein inhibitor PET/CT: cancer diagnosis and management. Front Oncol. 2021;11:758958. doi:10.3389/fonc.2021.758958.
   PubMed Web of Science ®Google Scholar
• Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET/CT. J Nucl Med. 2021;62(2):266–271. doi:10.2967/jnumed.120.244723.
   PubMed Web of Science ®Google Scholar